UCB to seek approval of Cimzia in psoriatic arthritis

UCB Group (Euronext:UCB) said Cimzia certolizumab significantly improved signs and symptoms of psoriatic arthritis from baseline to week 12 vs. placebo in the Phase III RAPID-PsA trial in 409 patients...